






















145Validation of three models predicting in-hospital
death in patients with an abdominal aortic
aneurysm eligible for both endovascular
and open repair
Sytse C. van Beek, MD,a Jan D. Blankensteijn, MD, PhD,b and Ron Balm, MD, PhD,a for the Dutch
Randomised Endovascular Aneurysm Management (DREAM) trial collaborators,* Amsterdam, The
Netherlands
Objective: The Medicare, the Vascular Governance North West (VGNW), and the British Aneurysm Repair (BAR) models
can be used to predict in-hospital death after an intervention for an asymptomatic abdominal aortic aneurysm (AAA).
Validation of these models in patients with suitable aortic anatomy for endovascular repair and a general condition ﬁt for
open repair is lacking. We validated the Medicare, VGNW, and BAR models in patients from a randomized controlled
trial comparing open and endovascular AAA repair.
Methods: A per-protocol analysis was done of 345 Dutch and Belgian patients with in-hospital death as the primary end
point. The prediction models were validated taking into account discrimination (the ability to distinguish between death
and survival) and calibration (the agreement between predicted and observed death rates). Discrimination was assessed
using the area under the receiver-operating characteristics curve (AUC). An AUC >0.70 was considered to be sufﬁciently
accurate. Calibration was assessed using the Hosmer-Lemeshow (HL) test, and P > .05 was considered to be sufﬁciently
accurate.
Results: The AUC was 0.77 (95% conﬁdence interval [CI], 0.64-0.90; HL test, P [ .52) for the Medicare model, 0.88
(95% CI, 0.81-0.95; HL test, P [ .31) for the VGNW model, and 0.79 (95% CI, 0.67-0.91; HL test, P [ .15) for the
BAR model.
Conclusions: In AAA patients eligible for endovascular and open repair, the predictions of in-hospital death by the
Medicare, VGNW, and BAR models were sufﬁciently accurate. Therefore, these models can be used to support deciding
between endovascular and open repair. (J Vasc Surg 2013;58:1452-7.)Patients with an abdominal aortic aneurysm (AAA) can
be treated with endovascular repair, open repair, or conser-
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2repair, the clinical decision-making process is predomi-
nantly based on estimates of the incidence of mortality,
reinterventions, and complications as well as on the ex-
pected quality-adjusted life-years.1 The challenge in current
practice is to determine which patients will beneﬁt the most
from endovascular repair and which from open repair.
Randomized trials have shown long-term survival and
quality-adjusted life-years are equal after both interven-
tions.2-4 However, the incidence of complications and rein-
terventions is higher after endovascular repair, whereas the
incidence of in-hospital death is higher after open repair.
Therefore, predicting in-hospital death and long-term rein-
terventions before the intervention could support clinical
decision making.
A prediction model is a standardized and objective way
to assess individual outcomes after an intervention. Several
models predicting in-hospital death after aortic repair have
been developed; for example, the prediction model most
frequently used is the well-validated Glasgow Aneurysm
Score (GAS), which was developed in 1994.5 The results
of validation studies evaluating the accuracy of the GAS
in endovascular repair are conﬂicting.6-9 Three new
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care model in the United States10 and the Vascular Gover-
nance North West (VGNW) and the British Aneurysm
Repair (BAR) models in the United Kingdom.11,12
Two validation studies have reported sufﬁciently accu-
rate predictions of in-hospital death for the Medicare and
VGNW models.8,13 These validations included patients
whose aortic anatomy was unsuitable for endovascular
repair and whose general condition was unﬁt for open
repair. As such, these studies included patients where there
was no choice between endovascular and open repair. To
our knowledge, the BAR model has not yet been validated
externally.
To apply the Medicare, VGNW, and BAR models to
support the decision between endovascular and open repair
in individual patients, validation is needed in patients
eligible for both options. Therefore, patients enrolled in
randomized trials comparing endovascular and open repair,
such as the Dutch Randomized Endovascular Aneurysm
Management (DREAM) trial, can be used to validate the
models.
As well as supporting decision making, prediction
models have additional value in improving patient educa-
tion. In the consulting room, prediction models can be
used to advise patients and relatives of the short-term risk
of dying after the intervention.
The objective of this study was to validate the Medi-
care, VGNW, and BAR prediction models in Dutch and
Belgian patients with an AAA who were eligible for both
open and endovascular repair.
METHODS
This study retrospectively analyzed 345 patients included
in the DREAM trial.3 Details of the DREAM trial (registra-
tion number clinicaltrials.gov NCT00421330) are described
in detail elsewhere.14 Brieﬂy, the DREAM trial was a multi-
center, randomized trial conducted at 26 hospitals in The
Netherlands and in four hospitals in Belgium. Inclusion
criteria for the DREAM trial were informed consent, an
AAA sized at least 5 cm, and suitability for both endovascular
andopen repair. Excludedwerepatientswith an inﬂammatory
aneurysm, anatomic variations, connective tissue disease,
a history of organ transplantation, or a life expectancy
of <2 years.
The study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki. Approval for the
DREAM trial was given by the Institutional Review Board
of all hospitals.
Statistical analysis. The analysiswas doneper-protocol.
The primary end point was the combination of 30-day and in-
hospital death. Statistical analysis was done using IBM SPSS
19.0 software (IBM, Armonk, New York) and R software
(The R Foundation for Statistical Computing, Vienna,
Austria).
The predictions of death by the Medicare, VGNW, and
BAR models were calculated with the formulas presented in
Table I. The accuracy of the predictions was assessed taking
discrimination and calibration into account.15Discriminationis the ability of a model to distinguish between those patients
who die and those who survive. Discrimination was assessed
using the area under the receiver-operating characteristics
curve (AUC). An AUC >0.70 is generally considered to be
sufﬁciently accurate. Calibration refers to the agreement
between the predicted and observed death rates and was
assessed using a graph plotting themean predicted death rates
in tertiles with the corresponding observed death rates. The
tertiles were created by sorting the predictions in ascending
order and categorizing the patients in three subgroups of
comparable size accordingly. The subgroups included 126,
119, and 100 patients for the calibration of the Medicare
model, 114, 116, and 115 patients for the VGNW model,
and 106, 118, and 121 patients for the BARmodel. The sizes
of these subgroups differed slightly because patients with
equalpredictionswere categorized in the same tertile.Calibra-
tion was also assessed using the Hosmer-Lemeshow (HL)
test. TheHL test compares predicted and observed outcomes
in a c2 distribution. An HL test P value <.05 reﬂects statisti-
cally signiﬁcant differences between predicted and observed
outcomes. Hence, a P value >.05 indicates sufﬁciently accu-
rate calibration of the model.
In two patients, the preoperative serum creatinine was
missing and was imputed as themean creatinine. The preop-
erative aneurysm diameter was missing in two other patients
and was imputed as the mean diameter. For the BARmodel,
the white cell count and the sodium level were unknown
and assumed to be within normal reference ranges.
RESULTS
In the study, 351 patients were randomized: 173 were
assigned to endovascular repair and 178 to open repair.
The treatment allocation ﬂowchart is published elsewhere.16
Six patients were excluded because they did not undergo
aneurysm repair. In the intention-to-treat analysis, 171
patients were included in the endovascular repair group
and 174 in the open repair group. One patient randomized
to endovascular repair underwent open repair, and ﬁve
patients randomized to open repair crossed over to endovas-
cular repair. Ultimately, the per-protocol analysis included
175 patients in the endovascular repair group and 170
patients in the open repair group. Three of the patients
treated with endovascular repair were converted to open
repair perioperatively, and one procedure was aborted.
The baseline characteristics of the patients included in the
per-protocol analysis are reported in Table II. The death
rate was 1.1% (two of 175; 95% conﬁdence interval [CI],
0.3%-4.1%) after endovascular repair and 4.7% (eight of
170; 95% CI, 2.4%-9.0%) after open repair.
Medicare model. The median predicted death rate of
the Medicare model was 1.0% (interquartile range [IQR],
0.8%-1.3%; range, 0.8%-4.2%) in patients treated with
endovascular repair and 3.2% (IQR, 2.4%-4.1%; range,
2.4%-12.0%) in patients treated with open repair. The
AUC of the predictions was 0.77 (95% CI, 0.64-0.90;
Fig 1). The plot showed close to ideal calibration (Fig 2)
and a P ¼ .47 for the HL test. In the tertile of patients with
the highest predictions, the mean predicted death rate was









Male 93.1 (163/175) 90.0 (153/170) 91.6 (316/345)
Female 6.9 (12/175) 10.0 (17/170) 8.4 (29/345)
Age, years 71 (67-75) 70 (66-75) 70 (66-75)
Previous aortic surgery or stent 0 (0/175) 0.6 (1/170) 0.6 (1/345)
Congestive heart failure 8.0 (14/175) 7.1 (12/170) 7.5 (26/345)
Cardiac disease 42.3 (74/175) 45.9 (78/170) 43.8 (151/345)
Abnormal ECG 42.3 (74/175) 45.3 (77/170) 44.1 (152/345)
Respiratory disease 26.9 (47/175) 18.2 (31/170) 22.6 (78/345)
Creatinine, mmol/L 96 (83-109) 95 (84-107) 95 (84-108)
Chronic renal insufﬁciency 7.4 (13/175) 7.1 (12/170) 7.2 (25/345)
End-stage renal disease 0 (0/175) 0 (0/170) 0 (0/345)
Creatinine >120 mmol/L 12.6 (22/175) 11.8 (20/170) 12.2 (42/345)
Vascular disease 32.0 (56/175) 27.1 (46/170) 29.6 (102/345)
Diabetes 10.3 (18/175) 9.4 (16/170) 9.9 (34/345)
Antiplatelet medication 40.0 (70/175) 40.6 (69/170) 40.3 (139/345)
AAA diameter, cm 5.8 (5.5-6.5) 5.8 (5.4-6.4) 5.8 (5.4-6.5)
ASA
2 92.0 (161/175) 85.9 (146/170) 89.0 (307/345)
3 8.0 (14/175) 14.1 (24/170) 11.0 (38/345)
4 0 (0/175) 0 (0/170) 0 (0/345)
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologist Physical Status Classiﬁcation; ECG, electrocardiogram.
aCategoric data are presented as percentage (n/N) and continuous data as median (interquartile range).
Table I. Formula and deﬁnitions of the Medicare, the Vascular Governance North West (VGNW), and the British
Aneurysm Repair (BAR) prediction models
Model score Formula
Medicare 5.02 þ age <75 years  0.15 þ age 75-80 years  0.63 þ age >80 years  1.14 þ female sex  0.42 þ chronic renal
insufﬁciencya  0.71 þ end-stage renal diseaseb  0.95 þ congestive heart failurec  0.55 þ vascular diseased  0.30 þ
open repair  1.17
VGNW 9.3431 þ age (years)  0.0486 þ female sex  0.7322 þ diabetese  0.6620 þ creatinine (mmol/L)  0.0073 þ
respiratory diseasef  0.4718 þ antiplatelet medication  0.7762 þ open repair  1.3130
BAR 10.9187 þ open repair  1.6466 þ age (years)  0.0568 þ female sex  0.7062 þ creatinine >120 mmol/L 
0.5979 þ abnormal ECGg  0.3033 þ previous aortic surgery or stent  0.8812 þ abnormal white cell counth 
0.3697 þ abnormal sodium leveli  0.3099 þ AAA diameter (cm)  0.1285 þ ASA 2  0.2292 þ ASA 3  0.7334 þ
ASA 4  1.6775
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologist Physical Status Classiﬁcation; BAR, British Aneurysm Repair; ECG, electro-
cardiogram; VGNW, Vascular Governance North West.
aSociety for Vascular Surgery/International Society for Cardiovascular Surgery (SVS/ISCS) renal status $1 (equal or worse condition, then moderately
elevated creatinine level as high as 220 mmol/L).
bNeed for dialysis.
cSVS/ISCS cardiac status $2 (equal or worse condition, then stable angina, ejection fraction between 25% and 45%, asymptomatic arrhythmia, or history of
congestive heart failure).
dSVS/ISCS carotid disease $2 (equal or worse condition, then transient or temporary stroke), ankle-brachial index <0.90, or previous history of peripheral
artery surgery.
eSVS/ISCS diabetes $1 (equal or worse condition, then adult-onset diabetes controlled by diet or oral agents).
fSVS/ISCS pulmonary status $1 (equal or worse condition, then mild dyspnea on exertion, parenchymal X-ray changes, or pulmonary function tests between
65% and 85% of predicted).
gSVS/ISCS cardiac status $1 (remote myocardial infarction by history of >6 months, occult myocardial infarction by electrocardiogram, or ﬁxed defect on
dipyridamole thallium or similar scan).
hWhite cell count <3.0  109/L or >11.0  109/L.
iSodium level <135 mmol/L or >145 mmol/L.
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(95% CI, 2.8%-12.5%).
VGNW model. The median predicted death rate of
the VGNW model was 0.9% (IQR, 0.6%-1.5%; range,
0.3%-5.7%) in patients treated with endovascular repair
and 3.5% (IQR 2.0%-4.9%; range, 0.5%-14.2%) in patientstreated with open repair. The AUC of the predictions was
0.88 (95% CI, 0.81-0.95; Fig 1). The plot showed close to
ideal calibration (Fig 2) and a P ¼ .24 for HL test. In the
tertile of patients with the highest predictions, the mean
predicted death rate was 5.1%, and the corresponding
observed death rate was 7.8% (95% CI, 4.2%-14.2%).
Fig 1. The discrimination of the Medicare, the Vascular Gover-
nance North West (VGNW), and the British Aneurysm Repair
(BAR) prediction models indicated by the area under curve and the
surrounding conﬁdence intervals (CIs) (bars). An area under the
curve >0.70 was considered as sufﬁciently accurate (dashed line).
Fig 2. Calibration plots are shown for the Medicare, the Vascular
Governance North West (VGNW), and the British Aneurysm
Repair (BAR) prediction models. The mean predicted death rates
in tertiles are plotted with the corresponding observed death rates.
The black dashed line corresponds with ideal calibration.
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BAR model was 0.4% (IQR, 0.3%-0.7%; range, 0.1%-2.2%)
in patients treated with endovascular repair and 2.3%
(IQR, 1.4%-3.5%; range, 0.3%-13.2%) in patients treated
with open repair. The AUC of the predictions was 0.79
(95% CI, 0.67-0.91; Fig 1). The plot showed close to ideal
calibration (Fig 2), withP¼ .15 for theHL test. In the tertile
of patients with the highest predictions, the mean predicted
death rate was 3.3%, and the corresponding observed death
rate was 5.8% (95% CI, 2.8%-11.5%).
DISCUSSION
The predictions of death by the Medicare, VGNW, and
BAR prediction models were sufﬁciently accurate in Dutch
and Belgian patients with an AAA eligible for both open
and endovascular repair.
The discrimination of the Medicare model (AUC ¼
0.77) was comparable with two previous validation studies
from the United Kingdom. In these validations, the AUC
of the predictions was 0.71 (95% CI, 0.69-0.74)8 and
0.79 (95% CI, 0.73-0.86).13 The discrimination of the
VGNW model (AUC ¼ 0.88) was higher than in two
previous validations reporting an AUC of 0.71 (95% CI,
0.68-0.74)8 and 0.73 (95% CI, 0.65-0.81).13 To our
knowledge, no previous external validation of the BAR
model has been done.
A striking observation was the high accuracy of the
VGNW model. First, the AUC (0.88) in our validation
was high compared with other surgical prediction models.
For example, the European System for Cardiac Operative
Risk Evaluation (EuroSCORE) is a reliable prediction
model widely used in daily practice in cardiac surgery. Avalidation study showed an AUC of 0.79 for the Euro-
SCORE.17 Second, the AUC of the predictions by the
VGNW model was higher than the AUC of the Medicare
and of the BAR models in our validation. This indicates
that the predictions by the VGNW model were more accu-
rate. However, given the limitations of our validation and
the equivalent AUCs in previous validations, no deﬁnite
conclusions can be drawn.
From a practical perspective, the Medicare and VGNW
models require only a few patient characteristics, and the
predictions can be calculated within a minute. The BAR
model, however, requires several more patient characteristics
and is thereby more complex compared with the Medicare
and VGNW models. The BAR model was primarily devel-
oped for risk adjustment in mortality outcome analyses
in the United Kingdom, which explains the higher
complexity.12 Extra diagnostic assessments are required,
including an electrocardiogram, the serum sodium level,
and the white cell count. The latter is not routinely measured
before intervention in TheNetherlands and Belgium. There-
fore, the Medicare and VGNWmodels have a clear practical
advantage over the BAR model in our clinical practice.
The variables included in the three models correspond
largely, which is suggestive for an accurate representation
of a patient’s risk proﬁle. Age, female sex, renal comorbidity,
generalized atherosclerosis, and open repair increase the
prediction of death. In the Medicare model, atherosclerosis
is represented by the variables “congestive heart failure”
and “vascular disease.” In the VGNW model, “antiplatelet
medication” is used as a surrogatemarker for atherosclerosis.
In the BAR model, “cardiac disease,” an “abnormal
Table III. Predictions of in-hospital death by the Medicare and Vascular Governance North West (VGNW) prediction
model in examples of six imaginary patients
Patient Characteristics









1 66 years, male, previous history of diabetes, creatinine of 100 mmol/L, no
antiplatelet medication
0.8 2.4 0.9 3.1
2 69 years, male, no previous history, creatinine of 85 mmol/L, no
antiplatelet medication
0.8 2.4 0.5 1.7
3 71 years, male, previous history of chronic renal insufﬁciency, heart failure,
and peripheral arterial occlusive disorder; creatinine of 190 mmol/L,
antiplatelet medication
3.5 10.5 2.3 8.2
4 75 years, female, previous history of transient ischemic attack, creatinine of
76 mmol/L, antiplatelet medication
2.5 7.6 2.6 8.9
5 81 years, female, previous history of heart failure, diabetes, and peripheral
arterial occlusive disorder, creatinine of 100 mmol/L, antiplatelet
medication
6.8 19.2 7.5 23.3
6 82 years, male, previous history of vascular disease and COPD GOLD II,
creatinine of 110 mmol/L, antiplatelet medication
2.7 8.2 3.5 12.0
COPD, Chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
JOURNAL OF VASCULAR SURGERY
1456 van Beek et al December 2013electrocardiogram,” and “previous aortic surgery or stent”
are used to represent atherosclerosis.
Decision making. Our validation was done in patients
in whom a decision between endovascular and open repair
was relevant; that is, patients with aortic anatomy suitable
for endovascular repair and in a general condition ﬁt for
open repair. Table III provides an example of six imagi-
nary patients in whom the models could support decision
making. The BAR model was not included in Table III
because of the previously discussed lower applicability in
Dutch clinical practice.
Patients 1 and 2 are relatively young, which means
open repair can be considered to prevent intensive yearly
follow-up. The models support a choice for open repair
by a relatively low predicted in-hospital death rate of
between 2.4% and 3.1%. Patients 3 and 4 are somewhat
older, at 71 and 75 years, and on the basis of their ages,
open repair can be considered. However, given the rela-
tively high predicted in-hospital death rate of between
7.6% and 10.5% after open repair, this might not be the
best choice. Patients 5 and 6 are relatively old and, consid-
ering the results of the United Kingdom EndoVascular
Aneurysm Repair 2 (EVAR-2) trial,2 conservative treat-
ment is a reasonable option in these patients. The predicted
in-hospital death rate for patient 5 is between 6.8% and
7.5% after endovascular repair and could support a choice
for conservative treatment. The predicted death rate for
patient 6 is between 2.7% and 3.5% after endovascular
repair, which could justify an intervention.
As mentioned before, the randomized trials have shown
that the in-hospital death rate and long-term reintervention
rate differ after endovascular and open repair. Our validation
shows that the Medicare, VGNW, and BAR models are
useful tools to predict in-hospital death and support decision
makingon this outcome.Othermodels are needed topredict
reinterventions and adverse events, such as aneurysm-related
death and endograft-related complications, to furthersupport decision making. An example of such a model is
the Endovascular Aneurysm Repair Risk Assessment
(ERA) model, which is designed to predict survival,
endograft-related complications, and reinterventions after
endovascular repair.18 However, the predictions of adverse
events by the ERA model have not been as accurate as
hoped.19,20 Possibly, a “meta-regression” of the ﬁnalized
randomized trials with uniform measurements of aortic
anatomy can provide sufﬁciently accurate predictions of
adverse events. An important characteristic of such a model
would be the accuracy in patients in whom risk assessment
is most needed and might support decision making. For
example, the risk of adverse events is higher in patients
with hostile aortic anatomy, and open repair might be
a reasonable alternative. Moreover, in patients with severe
comorbidity (patients 5 and 6 in Table III), conservative
treatment instead of EVAR is defendable based on results
of the EVAR-2 trial.2
Limitations. An important limitation of the validation
of the BAR model was the unknown white cell count and
sodium level. The effect on the discrimination is unknown,
and the calibration might be underestimated. However, in
the developing cohort of the BAR model, the prevalence
of abnormal outcomes of white cell count and sodium level
was only 10%. Moreover, the contribution of these variables
to the predictions are relatively small compared with the
other included variables, shown by the lower coefﬁcients
and Wald Z statistics in the model.12 Therefore, we expect
a limited effect of the unknown white cell count and sodium
level on our conclusions. However, more studies are needed
to conﬁrm the external validity of the BAR model.
The primary end point of our validation was in-hospital
death. Originally, the VGNW model was designed to
predict 30-day death. We used in-hospital death because
from a patient’s perspective, dying more than 30 days after
the intervention but during the same hospital admission
period cannot be considered a success.
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trial excluded patients with severe comorbidity. All three
models were developed in cohorts that included patients
with severe comorbidity; therefore, we expect that these
models take a patient’s severe comorbidity into account.
Moreover, in previous validation studies, the Medicare and
the VGNW models showed accurate predictions.8,13 Our
study focuses on patients eligible for both interventions.
Patients with severe comorbidity are usually not eligible for
both interventions; therefore, we expect the exclusion of
patients with severe comorbidity had a limited effect on
our conclusions.
Another limitation of our validation is the small sample
size leading to a low event rate. As a consequence, the cali-
bration plots showed large CIs surrounding the point esti-
mates of the observed death rates (Fig 2).
One ﬁnal limitation is that the inclusion period of the
DREAM trial was about a decade ago, and intensive care
unit and anesthetic care have improved since then. More-
over, all patients included in the validation were treated
with an early-generation endograft. Although the type of
endograft does not seem to have a major effect on the
in-hospital death rate, the inﬂuence of these differences
on the validity of our results in current practice is unknown.
CONCLUSIONS
The predictions of in-hospital death by the Medicare,
VGNW, and BAR models were sufﬁciently accurate in
patients eligible for both endovascular and open repair.
The BAR model is more complex, has limited additional
value in Dutch clinical practice, and needs further external
validation. Therefore, the Medicare and VGNW models
can be used to support deciding between endovascular
and open repair in The Netherlands and Belgium and to
advise patients and relatives about the risk of death after
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